Methods for the diagnosis, control and prophylaxis of inflammation and mitigation of inflammatory conditions in canines

• US 10,564,169 B2
• Filed: 05/05/2011
• Issued: 02/18/2020
• Est. Priority Date: 05/12/2010
• Status: Active Grant

• Current Assignee: Hill's Pet Nutrition Incorporated (Colgate-Palmolive Company)
• Original Assignee: Colgate-Palmolive Company
• Inventors: Frantz, Nolan Zebulon
• Primary Examiner(s): Sznaidman, Marcos L
• Assistant Examiner(s): Rodriguez, Rayna
• Application Number:
  US13/642,576
• Publication Number:
  US 20130041024A1
• Time in Patent Office: 3,211 Days
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: G01N 2800/105 Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere

Abstract

The invention relates to methods of diagnosis, control and prophylaxis of inflammation and mitigation of inflammatory conditions, particularly arthritis and joint pain, in canines, comprising measuring inflammatory biomarkers wherein elevated levels of the biomarkers in blood correlates to reduced inflammation and reduced levels in blood correlates to increase level in the tissues. The invention further provides a method to treat or control inflammation comprising administering a diet comprising increased levels of one or more of DHA, EPA, vitamin C, vitamin E, and/or L-carnitine.

Claims

1. A method of treating or controlling osteoarthritis in a canine, the method comprising:

detecting the osteoarthritis in the canine, wherein detecting the osteoarthritis in the canine comprises measuring decreased levels of one or more osteoarthritis biomarkers and increased levels of ANXA1 (Annexin A1) in blood of the canine as compared to healthy canines, and wherein the decreased levels of the one or more osteoarthritis biomarkers and the increased levels of ANXA1 (Annexin A1) in the blood indicate the presence of the osteoarthritis in tissue of the canine; and

administering to the canine in need thereof a diet comprising, on a dry weight basis;

protein;

18-22%;

fat;

14.4-17.6%;

carbohydrates;

45.9-56.1%;

crude fiber;

8.1-9.9%;

DHA;

0.27-0.33%;

EPA;

0.45-0.55%;

Vitamin C;

202.5-247.5 ppm;

Vitamin E;

526.5-643.5 ppm; and

L-carnitine;

315.9-386.1 mg/kg,

wherein the one or more osteoarthritis biomarkers to be measured are one or more of;

interleukin 6 (IL-6), a disintegrin and metallopeptidase with thrombospondin type 1 motif 4 (ADAMTS-4), interferon gamma (IFNG), hyaluronic acid synthase 2 (HAS2), biglycan (BGN), sex determining region Y-box 9 (SOX-9), a disintegrin and metallopeptidase with thrombospondin type 1 motif 5 (ADAMTS-5), matrix metalloproteinase 3 (MMP3), acid phosphastase 5 (ACP5), interleukin 1A (IL1A), tenasin C (TNC), hyaluronic acid synthase 3 (HAS3), cartilage oligomeric matrix protein (COMP), insulin-like growth factor 1 (IGF-1), ghrelin (GHR), X-prolyl dipeptidyl aminopeptidase (Xaa-Pro Peptidase), receptor activator of NF-Kappa B ligand (RANKL), mothers against decapentaplegic, drosophila, homolog of SMAD family member 7 (SMAD7), prostaglandin E2 (PGE2), toll-like receptor 9 (TLR9), plasminogen (PLOD1), and SCL2A9 glucose transporter (SCL2A9).

2. The method of claim 1, wherein the diet has the nutritional composition comprising, on a dry weight basis:

Protein;

20%;

Fat;

16%;

Carbohydrate;

51%;

Crude Fiber;

9%;

Carnitine;

351 mg/kg;

Vitamin C;

225 ppm;

Vitamin E;

585 ppm;

DHA;

0.3%; and

EPA;

0.5%.

3. The method of claim 1, wherein decreased levels of the ANXA1 (Annexin A1) levels correlates with reduced osteoarthritis in tissue of the canine.

4. The method of claim 1, wherein the diet is administered to the canine in need thereof for a period of at least two weeks.

5. The method of claim 1 wherein the diet comprises 0.8% of DHA +EPA.

6. The method of claim 1, wherein the one or more osteoarthritis biomarkers to be measured is selected from one or more of:

interleukin 6 (IL-6), a disintegrin and metallopeptidase with thrombospondin type 1 motif 4 (ADAMTS-4), interferon gamma (IFNG), hyaluronic acid synthase 2 (HAS2), biglycan (BGN), sex determining region Y-box 9 (SOX-9), a disintegrin and metallopeptidase with thrombospondin type 1 motif 5 (ADAMTS-5), acid phosphastase 5 (ACP5), interleukin 1A (IL1A), tenasin C (TNC), hyaluronic acid synthase 3 (HAS3), insulin-like growth factor 1 (IGF-1), ghrelin (GHR), X-prolyl dipeptidyl aminopeptidase (Xaa-Pro Peptidase), receptor activator of NF-Kappa B ligand (RANKL), mothers against decapentaplegic, drosophila, homolog of SMAD family member 7 (SMAD7), prostaglandin E2 (PGE2), toll-like receptor 9 (TLR9), plasminogen (PLOD1), and SCL2A9 glucose transporter (SCL2A9).

7. The method of claim 1, wherein the one or more osteoarthritis biomarkers to be measured is selected from one or more of:

a disintegrin and metallopeptidase with thrombospondin type 1 motif 4 (ADAMTS-4), interferon gamma (IFNG), hyaluronic acid synthase 2 (HAS2), biglycan (BGN), sex determining region Y-box 9 (SOX-9), a disintegrin and metallopeptidase with thrombospondin type 1 motif 5 (ADAMTS-5), acid phosphastase 5 (ACP

     5), tenasin C (TNC), hyaluronic acid synthase 3 (HAS3), insulin-like growth factor 1 (IGF-1), ghrelin (GHR), X-prolyl dipeptidyl aminopeptidase (Xaa-Pro Peptidase), receptor activator of NF-Kappa B ligand (RANKL), mothers against decapentaplegic, drosophila, homolog of SMAD family member 7 (SMAD7), prostaglandin E2 (PGE2), toll-like receptor 9 (TLR9), plasminogen (PLOD1), and SCL2A9 glucose transporter (SCL2A9).

8. A method for treating an inflammatory condition in a canine, the method comprising:

detecting the inflammatory condition in the canine, wherein detecting the inflammatory condition comprises measuring decreased levels of one or more inflammatory biomarkers and increased levels of ANXA1 (Annexin A1) in blood of the canine as compared to healthy canines, and wherein the decreased levels of the one or more inflammatory biomarkers and the increased levels of ANXA1 (Annexin A1) in the blood indicate the presence of the inflammatory condition in tissue of the canine;

administering to the canine in need thereof a diet comprising, on a dry matter basis;

protein in an amount of 18-22%;

fat in an amount of 14.4-17.6%;

carbohydrates in an amount of 45.9-56.1%;

crude fiber in an amount of 8.1-9.9%;

DHA in an amount of 0.27-0.33%;

EPA in an amount of 0.45-0.55%;

vitamin C in an amount of 202.5-247.5 ppm;

vitamin E in an amount of 526.5-643.5 ppm; and

L-carnitine in an amount of 315.9-386.1 mg/kg; and

detecting a reduction in the inflammatory condition in the canine, wherein detecting the reduction in the inflammatory condition in the canine comprises measuring decreased levels of Annexin A1 (ANXA1) in the blood of the canine in need thereof as compared to the healthy canines, and wherein the decreased levels of the ANXA1 in the blood of the canine indicates the reduction in the inflammatory condition,

wherein the one or more osteoarthritis biomarkers to be measured is one or more of the group consisting of;

interleukin 6 (IL-6), a disintegrin and metallopeptidase with thrombospondin type 1 motif 4 (ADAMTS-4), interferon gamma (IFNG), hyaluronic acid synthase 2 (HAS2), biglycan (BGN), sex determining region Y-box 9 (SOX-9), a disintegrin and metallopeptidase with thrombospondin type 1 motif 5 (ADAMTS-5), matrix metalloproteinase 3 (MMP3), acid phosphastase 5 (ACP5), interleukin 1A (IL1A), tenasin C (TNC), hyaluronic acid synthase 3 (HAS3), cartilage oligomeric matrix protein (COMP), insulin-like growth factor 1 (IGF-1), ghrelin (GHR), X-prolyl dipeptidyl aminopeptidase (Xaa-Pro Peptidase), receptor activator of NF-Kappa B ligand (RANKL), mothers against decapentaplegic, drosophila, homolog of SMAD family member 7 (SMAD7), prostaglandin E2 (PGE2), toll-like receptor 9 (TLR9), plasminogen (PLOD1), and SCL2A9 glucose transporter (SCL2A9).

9. The method of claim 8, wherein the one or more inflammatory biomarkers to be measured is selected from one or more of:

interleukin 6 (IL-6), interferon gamma (IFNG), hyaluronic acid synthase 2 (HAS2), biglycan (BGN), sex determining region Y-box 9 (SOX-9), acid phosphastase 5 (ACP5), interleukin 1A (IL1A), tenasin C (TNC), hyaluronic acid synthase 3 (HAS3), insulin-like growth factor 1 (IGF-1), ghrelin (GHR), X-prolyl dipeptidyl aminopeptidase (Xaa-Pro Peptidase), receptor activator of NF-Kappa B ligand (RANKL), mothers against decapentaplegic, drosophila, homolog of SMAD family member 7 (SMAD7), prostaglandin E2 (PGE2), toll-like receptor 9 (TLR9), plasminogen (PLOD1), and SCL2A9 glucose transporter (SCL2A9).